Payment overview · 2025
General Payments
$877.69
35 reported records · 18 companies
Healthcare provider profile · identity verified
David R. Hulbert, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EAGLE, ID · NPI 1730313586
Verified facts
What the public records show
CMS Open Payments records show David R. Hulbert, M.D. received $877.69 in general payments during 2025 across 35 reported records.
PFIZER INC. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $188.68 | 21.5% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $183.83 | 20.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.60 | 7.7% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $49.11 | 5.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.50 | 5.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.02 | 5.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.55 | 4.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.80 | 4.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.09 | 3.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.60 | 3.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.45 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.05 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.01 | 2.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.62 | 2.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.63 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.05 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.53 | 1.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.57 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $877.69 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $183.83 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $84.20 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $84.20 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $84.20 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $81.62 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $69.56 | 3 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $49.11 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.05 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.50 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.50 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.09 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 19 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 23 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 498 | 156 |
| Losartan Potassium | Losartan Potassium | 364 | 115 |
| Omeprazole | Omeprazole | 355 | 108 |
| Lisinopril | Lisinopril | 328 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 54 |
| Metformin Hcl Er | Metformin Hcl | 170 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 55 |
| Alprazolam | Alprazolam | 151 | 28 |
| Meloxicam | Meloxicam | 127 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 47 |
| Simvastatin | Simvastatin | 119 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 24 |
| Tramadol Hcl | Tramadol Hcl | 114 | 30 |
| Gabapentin | Gabapentin | 112 | 39 |
| Trazodone Hcl | Trazodone Hcl | 112 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 29 |
| Metformin Hcl | Metformin Hcl | 95 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 19 |
| Eliquis | Apixaban | 85 | 23 |
| Lorazepam | Lorazepam | 85 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 39 |
| Allopurinol | Allopurinol | 73 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 25 |
| Clonazepam | Clonazepam | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 62 | 20 |
| Celecoxib | Celecoxib | 61 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 19 |
| Bupropion Xl | Bupropion Hcl | 55 | 14 |
| Naproxen | Naproxen | 50 | 23 |
| Sertraline Hcl | Sertraline Hcl | 50 | 13 |
| Warfarin Sodium | Warfarin Sodium | 49 | 13 |
| Furosemide | Furosemide | 47 | 16 |
| Bumetanide | Bumetanide | 45 | 15 |
| Ozempic | Semaglutide | 45 | 11 |
| Spironolactone | Spironolactone | 45 | 16 |
| Alendronate Sodium | Alendronate Sodium | 43 | 14 |
| Prednisone | Prednisone | 43 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 14 |
| Baclofen | Baclofen | 41 | 18 |
| Valsartan | Valsartan | 40 | suppressed |
| Estradiol | Estradiol | 39 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 12 |
| Atenolol | Atenolol | 38 | 11 |
| Lovastatin | Lovastatin | 38 | 12 |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Montelukast Sodium | Montelukast Sodium | 32 | 11 |
| Potassium Chloride | Potassium Chloride | 32 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 11 |
| Valacyclovir | Valacyclovir Hcl | 30 | 11 |
| Azithromycin | Azithromycin | 29 | 22 |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | 13 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Glipizide | Glipizide | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $877.69 · 35 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, General - Pain Management, INCEPTIV, LEQVIO, MINIMED 780G, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, TZIELD, UBRELVY, VYNDAQEL, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error